ONO-7913

DRUG3 trials

Sponsors

Ono Pharmaceutical Co. Ltd, Ono Pharmaceutical Co., Ltd.

Conditions

Metastatic Pancreatic CancerSolid TumorUnresectable Colorectal Cancer

Phase 1

ONO-7913 Phase I Study (ONO-7913)

CompletedNCT04403308

Ono Pharmaceutical Co. LtdSolid Tumor

Start: 2020-07-28End: 2022-01-13Updated: 2024-05-03

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Active, not recruitingNCT06532344

Ono Pharmaceutical Co., Ltd.Metastatic Pancreatic Cancer

Start: 2021-07-30End: 2027-06-30Updated: 2026-10-07

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Active, not recruitingNCT06540261

Ono Pharmaceutical Co., Ltd.Unresectable Colorectal Cancer

Start: 2021-09-23End: 2027-12-31Updated: 2026-10-07

Related Papers

Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study

BMC Research Notes2026-03-26